Focused on solutions to address DMPK issues of today

While our scientists routinely conduct industry-standard in vitro ADME assays, we are also developing novel assays to stay current with the DMPK issues of today to help better predict clinical outcomes. See detailed assay list.

• Non-P450 metabolism, including glucuronosyltransferase (UGT) and aldehyde oxidase (AO)-mediated metabolism ― We can help you design and execute in vitro studies to diagnose non-P450 pathways and guide you on next stages to better understand the drug-drug interaction potential of your drug.
• Slowly metabolized drugs, with intrinsic clearance estimations in conventional systems restricted by incubation time ― We have evaluated hepatocyte co-culture models and compared these novel systems to plated monoculture and suspended hepatocytes to enable human clearance predictions for low-turnover drugs.  
• CYP3A5, a polymorphic drug-metabolizing enzyme that can contribute to pharmacokinetic variability in the clinic ― With the discovery of CYP3cide, a selective mechanism-based inactivator of CYP3A4, a relative activity factor (RAF) methodology can be used to estimate CYP3A5 contribution to total CYP3A metabolism using individual CYP3A5*1*1 donor HLMs.  
• Metabolite-in-Safety-Testing (MIST), increasingly requested by regulatory agencies for early assessments of human metabolism ― We have the expertise to confidently profile first-in-human plasma to begin the iterative process of addressing your MIST coverage needs.

Whether your target compounds are for neuroscience, infectious disease, inflammation, or oncology, our scientists are ready to collaborate with you to accelerate your drug discovery, preclinical, and clinical programs. What differentiates us from other lab CROs is the diversity in real-world Pharma experience of our scientists and scientific leadership. From both a scientific and a regulatory standpoint, we have the experience to guide your drug discovery & development programs.